Myositis is an umbrella term for inflammatory muscle diseases which, however may have diverse pathogenic mechanisms. Identification, understanding and modulating those underpinnings may be crucial for therapeutic approaches. There has been a paradigm shift from relatively simple concepts of B cell- (dermatomyositis) or T cell pathology (polymyositis) and additionally, amyloid deposition in IBM towards a more detailed and sub-entity-specific understanding of certain molecular dysregulations.
In this talk I will address the molecular and corresponding morphological features that we have identified and studied recently and discuss their relevance for possible therapeutic approaches in the future.